Applied Therapeutics, Inc. (APLT)
After hours:
| Previous Close | 10.78 |
| Open | 10.68 |
| Bid | 9.79 x 900 |
| Ask | 11.51 x 1200 |
| Day's Range | 10.13 - 11.51 |
| 52 Week Range | 10.13 - 29.80 |
| Volume | |
| Avg. Volume | 89,855 |
| Market Cap | 300.954M |
| Beta (5Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.14 |
| Earnings Date | Nov. 12, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 44.50 |
- GlobeNewswire
Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism
NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, has announced a symposium and poster presentations at the 14th International Congress of Inborn Errors of Metabolism (ICIEM), November 21-23, 2021, Sydney, Australia. “We are pleased to present this important data at the ICIEM conference, demon
- Simply Wall St.
Great news for Applied Therapeutics, Inc. (NASDAQ:APLT): Insiders acquired stock in large numbers last year
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
- GlobeNewswire
Applied Therapeutics Reports Third Quarter 2021 Financial Results
Data from pilot trial of AT-007 in SORD deficiency expresses substantial and significant reduction in sorbitol Data from the ACTION-Galactosemia Kids study demonstrates statistically significant reduction in plasma galactitol NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported fin
